Health insurers slide after CMS proposes a tiny 2027 Medicare Advantage payment increase
Shares of major U.S. health insurers fell sharply after the government proposed a net 0.09% increase in Medicare Advantage payments for 2027. The draft rates—far below investors’ expectations—raise questions about plan benefits, margins, and possible pullbacks in some markets if finalized.
U.S. health insurer stocks dropped hard on Tuesday after the Centers for Medicare & Medicaid Services (CMS) released its proposed payment policies for Medicare Advantage in 2027. The government’s draft forecast calls for a net average year-over-year payment increase of just 0.09%, a figure that stunned investors who had been expecting something closer to the mid-single digits.
The immediate market reaction was broad: UnitedHealth, Humana, CVS and other companies tied to the Medicare Advantage business moved sharply lower as traders recalibrated assumptions about 2027 profitability. Medicare Advantage is a major revenue engine for insurers, and small changes in projected rates can translate into significant differences in margins, benefit design, and whether plans remain attractive to offer in certain counties.
CMS emphasized that the proposal is part of an annual process that updates methodologies and is designed to improve payment accuracy and sustainability. The agency’s estimate equates to more than $700 million in additional payments to plans for 2027, though the policy document also includes technical adjustments that can shift winners and losers depending on each insurer’s membership mix, risk scores, and Star Ratings exposure.
Analysts and executives warned that, if the proposal were finalized close to its current form, insurers might respond by trimming supplemental benefits, tightening networks, raising premiums, or changing how they position products for the next enrollment cycle. Some analysts also raised the possibility of plan exits in markets where the math becomes difficult, though the final outcome will depend on the ultimate rate announcement and each company’s ability to manage medical cost trends.
The proposed rates arrive amid heightened political scrutiny of healthcare costs and the relationship between public dollars and private-plan profits. Policymakers and investigators have increasingly focused on Medicare Advantage billing practices, risk-adjustment coding, and whether incentives encourage aggressive documentation that lifts government payments.
It is also important that this is not the last word. CMS typically collects feedback and can make changes before releasing final rates later in the year. Historically, initial proposals and final announcements have sometimes differed materially, which is one reason investors will now closely track lobbying efforts, the public comment period, and any signals from CMS about areas it may revisit.
For now, the market’s message was straightforward: even a small change in Medicare Advantage assumptions can quickly rewrite the outlook for an entire sector, particularly when valuations and earnings expectations were built around a more generous 2027 increase.